Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Inhibition of host NOX1 blocks tumor growth and enhances checkpoint inhibitor-based immunotherapy.

Stalin J, Garrido-Urbani S, Heitz F, Szyndralewiez C, Jemelin S, Coquoz O, Ruegg C, Imhof BA.

Life Sci Alliance. 2019 Jun 27;2(4). pii: e201800265. doi: 10.26508/lsa.201800265. Print 2019 Aug.

2.

Nox4 is a Target for Tuberin Deficiency Syndrome.

Shi Q, Viswanadhapalli S, Friedrichs WE, Velagapudi C, Szyndralewiez C, Bansal S, Bhat MA, Choudhury GG, Abboud HE.

Sci Rep. 2018 Feb 28;8(1):3781. doi: 10.1038/s41598-018-21838-4.

3.

Inhibition of Nox4-dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal-mediated protumorigenic interactions.

Sampson N, Brunner E, Weber A, Puhr M, Schäfer G, Szyndralewiez C, Klocker H.

Int J Cancer. 2018 Jul 15;143(2):383-395. doi: 10.1002/ijc.31316. Epub 2018 Mar 1.

4.

Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4.

Hanley CJ, Mellone M, Ford K, Thirdborough SM, Mellows T, Frampton SJ, Smith DM, Harden E, Szyndralewiez C, Bullock M, Noble F, Moutasim KA, King EV, Vijayanand P, Mirnezami AH, Underwood TJ, Ottensmeier CH, Thomas GJ.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx121.

5.

Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease.

Gray SP, Jha JC, Kennedy K, van Bommel E, Chew P, Szyndralewiez C, Touyz RM, Schmidt HHHW, Cooper ME, Jandeleit-Dahm KAM.

Diabetologia. 2017 May;60(5):927-937. doi: 10.1007/s00125-017-4215-5. Epub 2017 Feb 3.

PMID:
28160092
6.

NOX4-derived reactive oxygen species limit fibrosis and inhibit proliferation of vascular smooth muscle cells in diabetic atherosclerosis.

Di Marco E, Gray SP, Kennedy K, Szyndralewiez C, Lyle AN, Lassègue B, Griendling KK, Cooper ME, Schmidt HHHW, Jandeleit-Dahm KAM.

Free Radic Biol Med. 2016 Aug;97:556-567. doi: 10.1016/j.freeradbiomed.2016.07.013. Epub 2016 Jul 19.

7.

Airway smooth muscle NOX4 is upregulated and modulates ROS generation in COPD.

Hollins F, Sutcliffe A, Gomez E, Berair R, Russell R, Szyndralewiez C, Saunders R, Brightling C.

Respir Res. 2016 Jul 19;17(1):84. doi: 10.1186/s12931-016-0403-y.

8.

Therapeutic potential of NADPH oxidase 1/4 inhibitors.

Teixeira G, Szyndralewiez C, Molango S, Carnesecchi S, Heitz F, Wiesel P, Wood JM.

Br J Pharmacol. 2017 Jun;174(12):1647-1669. doi: 10.1111/bph.13532. Epub 2016 Jul 14. Review.

9.

NADPH Oxidase-4 Overexpression Is Associated With Epithelial Ciliary Dysfunction in Neutrophilic Asthma.

Wan WY, Hollins F, Haste L, Woodman L, Hirst RA, Bolton S, Gomez E, Sutcliffe A, Desai D, Chachi L, Mistry V, Szyndralewiez C, Wardlaw A, Saunders R, O'Callaghan C, Andrew PW, Brightling CE.

Chest. 2016 Jun;149(6):1445-59. doi: 10.1016/j.chest.2016.01.024. Epub 2016 Feb 2.

10.

Hepatocyte Nicotinamide Adenine Dinucleotide Phosphate Reduced Oxidase 4 Regulates Stress Signaling, Fibrosis, and Insulin Sensitivity During Development of Steatohepatitis in Mice.

Bettaieb A, Jiang JX, Sasaki Y, Chao TI, Kiss Z, Chen X, Tian J, Katsuyama M, Yabe-Nishimura C, Xi Y, Szyndralewiez C, Schröder K, Shah A, Brandes RP, Haj FG, Török NJ.

Gastroenterology. 2015 Aug;149(2):468-80.e10. doi: 10.1053/j.gastro.2015.04.009. Epub 2015 Apr 14.

11.

Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes.

Gorin Y, Cavaglieri RC, Khazim K, Lee DY, Bruno F, Thakur S, Fanti P, Szyndralewiez C, Barnes JL, Block K, Abboud HE.

Am J Physiol Renal Physiol. 2015 Jun 1;308(11):F1276-87. doi: 10.1152/ajprenal.00396.2014. Epub 2015 Feb 4.

12.

Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.

Jha JC, Gray SP, Barit D, Okabe J, El-Osta A, Namikoshi T, Thallas-Bonke V, Wingler K, Szyndralewiez C, Heitz F, Touyz RM, Cooper ME, Schmidt HH, Jandeleit-Dahm KA.

J Am Soc Nephrol. 2014 Jun;25(6):1237-54. doi: 10.1681/ASN.2013070810. Epub 2014 Feb 7.

13.

Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-inflammatory responses in diabetic Apoe(-/-) mice.

Di Marco E, Gray SP, Chew P, Koulis C, Ziegler A, Szyndralewiez C, Touyz RM, Schmidt HH, Cooper ME, Slattery R, Jandeleit-Dahm KA.

Diabetologia. 2014 Mar;57(3):633-42. doi: 10.1007/s00125-013-3118-3. Epub 2013 Nov 30.

PMID:
24292634
14.

NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy.

Wilkinson-Berka JL, Deliyanti D, Rana I, Miller AG, Agrotis A, Armani R, Szyndralewiez C, Wingler K, Touyz RM, Cooper ME, Jandeleit-Dahm KA, Schmidt HH.

Antioxid Redox Signal. 2014 Jun 10;20(17):2726-40. doi: 10.1089/ars.2013.5357. Epub 2013 Oct 30.

15.

NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis.

Gray SP, Di Marco E, Okabe J, Szyndralewiez C, Heitz F, Montezano AC, de Haan JB, Koulis C, El-Osta A, Andrews KL, Chin-Dusting JP, Touyz RM, Wingler K, Cooper ME, Schmidt HH, Jandeleit-Dahm KA.

Circulation. 2013 May 7;127(18):1888-902. doi: 10.1161/CIRCULATIONAHA.112.132159. Epub 2013 Apr 5.

PMID:
23564668
16.

Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes.

Sedeek M, Gutsol A, Montezano AC, Burger D, Nguyen Dinh Cat A, Kennedy CR, Burns KD, Cooper ME, Jandeleit-Dahm K, Page P, Szyndralewiez C, Heitz F, Hebert RL, Touyz RM.

Clin Sci (Lond). 2013 Feb;124(3):191-202. doi: 10.1042/CS20120330.

PMID:
22920224
17.

The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation.

Green DE, Murphy TC, Kang BY, Kleinhenz JM, Szyndralewiez C, Page P, Sutliff RL, Hart CM.

Am J Respir Cell Mol Biol. 2012 Nov;47(5):718-26. doi: 10.1165/rcmb.2011-0418OC. Epub 2012 Aug 16.

18.

Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent.

Aoyama T, Paik YH, Watanabe S, Laleu B, Gaggini F, Fioraso-Cartier L, Molango S, Heitz F, Merlot C, Szyndralewiez C, Page P, Brenner DA.

Hepatology. 2012 Dec;56(6):2316-27. doi: 10.1002/hep.25938.

19.

Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo.

Jiang JX, Chen X, Serizawa N, Szyndralewiez C, Page P, Schröder K, Brandes RP, Devaraj S, Török NJ.

Free Radic Biol Med. 2012 Jul 15;53(2):289-96. doi: 10.1016/j.freeradbiomed.2012.05.007. Epub 2012 May 19.

20.

Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors.

Gaggini F, Laleu B, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, Gradia A, Duboux G, Merlot C, Heitz F, Szyndralewiez C, Page P.

Bioorg Med Chem. 2011 Dec 1;19(23):6989-99. doi: 10.1016/j.bmc.2011.10.016. Epub 2011 Oct 17.

PMID:
22041175
21.

Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism.

Garrido-Urbani S, Jemelin S, Deffert C, Carnesecchi S, Basset O, Szyndralewiez C, Heitz F, Page P, Montet X, Michalik L, Arbiser J, Rüegg C, Krause KH, Imhof BA.

PLoS One. 2011 Feb 7;6(2):e14665. doi: 10.1371/journal.pone.0014665. Erratum in: PLoS One. 2011;6(2).doi: 10.1371/annotation/a392bbef-b0ec-4c70-b403-74a7bad85178. Imhof, Beat [corrected to Imhof, Beat A].

22.

First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis.

Laleu B, Gaggini F, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, Gradia A, Duboux G, Merlot C, Heitz F, Szyndralewiez C, Page P.

J Med Chem. 2010 Nov 11;53(21):7715-30. doi: 10.1021/jm100773e.

PMID:
20942471
23.

Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy.

Sedeek M, Callera G, Montezano A, Gutsol A, Heitz F, Szyndralewiez C, Page P, Kennedy CR, Burns KD, Touyz RM, Hébert RL.

Am J Physiol Renal Physiol. 2010 Dec;299(6):F1348-58. doi: 10.1152/ajprenal.00028.2010. Epub 2010 Jul 14.

24.

NADPH oxidases regulate CD44 and hyaluronic acid expression in thrombin-treated vascular smooth muscle cells and in atherosclerosis.

Vendrov AE, Madamanchi NR, Niu XL, Molnar KC, Runge M, Szyndralewiez C, Page P, Runge MS.

J Biol Chem. 2010 Aug 20;285(34):26545-57. doi: 10.1074/jbc.M110.143917. Epub 2010 Jun 17.

25.

GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis.

Gobert RP, van den Eijnden M, Szyndralewiez C, Jorand-Lebrun C, Swinnen D, Chen L, Gillieron C, Pixley F, Juillard P, Gerber P, Johnson-Léger C, Halazy S, Camps M, Bombrun A, Shipp M, Vitte PA, Ardissone V, Ferrandi C, Perrin D, Rommel C, Hooft van Huijsduijnen R.

J Biol Chem. 2009 Apr 24;284(17):11385-95. doi: 10.1074/jbc.M807241200. Epub 2009 Feb 20.

26.

Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.

Gaillard P, Jeanclaude-Etter I, Ardissone V, Arkinstall S, Cambet Y, Camps M, Chabert C, Church D, Cirillo R, Gretener D, Halazy S, Nichols A, Szyndralewiez C, Vitte PA, Gotteland JP.

J Med Chem. 2005 Jul 14;48(14):4596-607.

PMID:
15999997
27.

AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties.

Carboni S, Hiver A, Szyndralewiez C, Gaillard P, Gotteland JP, Vitte PA.

J Pharmacol Exp Ther. 2004 Jul;310(1):25-32. Epub 2004 Feb 26.

PMID:
14988419

Supplemental Content

Loading ...
Support Center